[1]何小鹏,高 亭.盐酸安罗替尼一线联合化疗后序贯盐酸安罗替尼治疗广泛期小细胞肺癌的效果[J].医学信息,2022,35(23):76-79.[doi:10.3969/j.issn.1006-1959.2022.23.012]
　HE Xiao-peng,GAO Ting.Effect of Sequential Anlotinib Hydrochloride After First-line Combined Chemotherapy on Extensive Stage Small Cell Lung Cancer[J].Journal of Medical Information,2022,35(23):76-79.[doi:10.3969/j.issn.1006-1959.2022.23.012]
点击复制

盐酸安罗替尼一线联合化疗后序贯盐酸安罗替尼治疗广泛期小细胞肺癌的效果()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年23期
页码:
76-79
栏目:
论著
出版日期:
2022-12-01

文章信息/Info

Title:
Effect of Sequential Anlotinib Hydrochloride After First-line Combined Chemotherapy on Extensive Stage Small Cell Lung Cancer
文章编号:
1006-1959（2022）23-0076-04
作者:
何小鹏; 高 亭
（咸阳市中心医院呼吸内科，陕西 咸阳 712000）
Author(s):
HE Xiao-peng; GAO Ting
(Department of Respiratory Medicine,Xianyang Central Hospital,Xianyang 712000,Shaanxi,China)
关键词:
小细胞肺癌; 盐酸安罗替尼; 生存期
Keywords:
Small cell lung cancer; Anlotinib hydrochloride; Chemotherapy; Survival time
分类号:
R735.2
DOI:
10.3969/j.issn.1006-1959.2022.23.012
文献标志码:
A
摘要:
目的 探讨一线使用盐酸安罗替尼联合化疗后序贯盐酸安罗替尼治疗广泛期小细胞肺癌的治疗效果及安全性。方法 选取2020年1月1日-2021年12月31日在咸阳市中心医院确诊的广泛期小细胞肺癌患者128例，按照随机数字表法分为对照组和试验组，各64例。对照组采用单纯EP方案化疗，试验组行盐酸安罗替尼联合EP方案化疗，比较两组生存期及安全性。结果 对照组中位无进展生存期（PFS）少于试验组，差异有统计学意义（P＜0.05）；对照组中位总生存期（OS）少于试验组，差异有统计学意义（P＜0.05）；两组不良反应均为Ⅰ~Ⅱ级不良反应，试验组血小板减少、手足综合征、口腔溃疡、牙龈出血、高血压的发生比例高于对照组。结论 盐酸安罗替尼一线联合化疗能够改善广泛期小细胞肺癌患者生存期且安全性较高。
Abstract:
Objective To investigate the efficacy and safety of first-line anlotinib hydrochloride combined with chemotherapy followed by sequential anlotinib hydrochloride in the treatment of extensive stage small cell lung cancer.Methods A total of 128 patients with extensive small cell lung cancer diagnosed in Xianyang Central Hospital from January 1, 2020 to December 31, 2021 were selected and divided into control group and experimental group according to the random number table method, with 64 cases in each group. The control group was treated with EP regimen alone, and the experimental group was treated with anlotinib hydrochloride combined with EP regimen. The survival time and safety of the two groups were compared.Results The median progression-free survival (PFS) of the control group was less than that of the experimental group, and the difference was statistically significant (P<0.05). The median overall survival (OS) of the control group was less than that of the experimental group, and the difference was statistically significant (P<0.05). The adverse reactions of the two groups were grade Ⅰ-Ⅱ adverse reactions. The incidence of thrombocytopenia, hand-foot syndrome, oral ulcer, gingival bleeding and hypertension in the experimental group was higher than that in the control group.Conclusion Anlotinib hydrochloride combined with first-line chemotherapy can significantly improve the survival time and safety of patients with extensive small cell lung cancer.

参考文献/References:

[1]Siegel RL,Miller KD,Jemal A.Cancer statistics, 2019[J].CA: A Cancer Journal for Clinicians,2019,69(1):7-34.[2]Duma N,Santana-Davila R,Molina JR.Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment[J].Mayo Clinic Proceedings,2019,94(8):1623-1640.[3]Thomas PL,Groves SM,Zhang YK,et al.Beyond PD-L1: B7-H6 emerges as a potential immunotherapy target in small cell lung cancer[J].Journal of Thoracic Oncology,2021,16(7):1211-1223.[4]Bernhardt EB,Jalal SI.Small Cell Lung Cancer[J].Cancer Treatment and Research,2016,170:301-322.[5]Lara PN Jr,Natale R,Crowley J,et al.Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124[J].Journal of Clinical Oncology,2009,27(15):2530-2535.[6]Früh M.Carboplatin- or Cisplatin-based chemotherapy in first-line treatement of scmall cell lung cancer: The COCIS individual patient data meta-analysis[J].J Clin Oncol,2012:1692-1698.[7]Xie C,Wan X,Quan H,et al.Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor[J].Cancer Science,2018,109(4):1207-1219.[8]Schneider BJ,Saxena A,Downey RJ.Surgery for early-stage small cell lung cancer[J].Journal of the National Comprehensive Cancer Network,2011,9(10):1132-1139.[9]Waqar SN,Morgensztern D.Treatment advances in small cell lung cancer (SCLC)[J].Pharmacology & Therapeutics,2017,180:16-23.[10]Stinchcombe TE.Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer[J].The oncologist,2017,22(12):1510-1517.[11]Ito T,Kudoh S,Ichimura T,et al.Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1[J].Human Cell,2017,30(1):1-10.[12]von Pawel J,Schiller JH,Shepherd FA,et al.Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer[J].Journal of Clinical Oncology,1999,17(2):658-667.[13]Tiseo M,Boni L,Ambrosio F,et al.Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial[J].Journal of Clinical Oncology,2017,35(12):1281-1287.[14]Ready NE,Pang HH,Gu L,et al.Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance)[J].Journal of Clinical Oncology,2015,33(15):1660-1665.[15]Shi J,Cheng Y,Wang Q,et al.Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)[J].Frontiers of Medicine,2022,16(5):766-772.[16]宋召喜,宪慧,刘伟新.纳武利尤单抗联合GP化疗方案在非小细胞肺癌治疗中的应用[J].实用癌症杂志,2022,37(1):90-92.[17]王玉霞,程程,庄洪卿.安罗替尼联合立体定向放射外科治疗非小细胞肺癌脑转移的疗效及安全性[J].中华医学杂志,2022,102(13):930-934.[18]徐寿华,杜海燕.安罗替尼三线治疗晚期非小细胞肺癌的临床研究[J].中国肿瘤临床与康复,2020,27(2):214-216.[19]张孟伟,谷俊娇,刘灿,等.安罗替尼一线治疗老年广泛期小细胞肺癌患者效果及安全性分析[J].肿瘤研究与临床,2021,33(7):541-543.[20]文璐,刘元明.盐酸安罗替尼治疗非小细胞肺癌的临床研究[J].实用医院临床杂志,2021,18(1):71-74.

相似文献/References:

[1]袁 康,谭 伟.多层螺旋CT用于小细胞肺癌与肺鳞癌的鉴别诊断价值分析[J].医学信息,2018,31(16):148.[doi:10.3969/j.issn.1006-1959.2018.16.047]
　YUAN Kang,TAN Wei.Value of Multi-slice Spiral CT in Differential Diagnosis of Small Cell Lung Cancer and Lung Squamous Cell Carcinoma[J].Journal of Medical Information,2018,31(23):148.[doi:10.3969/j.issn.1006-1959.2018.16.047]
[2]王东梅,张展英.小细胞肺癌中信号通路及蛋白相互作用网络分析[J].医学信息,2020,33(01):81.[doi:10.3969/j.issn.1006-1959.2020.01.025]
　WANG Dong-mei,ZHANG Zhan-ying.Analysis of Signal Pathways and Protein Interaction Networks in Small Cell Lung Cancer[J].Journal of Medical Information,2020,33(23):81.[doi:10.3969/j.issn.1006-1959.2020.01.025]

更新日期/Last Update: 1900-01-01